AnaptysBio, Inc.
- Open
- 56.82
- Day high
- 58.09
- Day low
- 56.20
- Prev close
- 57.03
- Volume
- 69K
- Mkt cap
- $1.7B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 131.5
- P/S
- 7.2
- Yield
- —
- Per share
- —
AnaptysBio, Inc. (ANAB) is a Healthcare company listed on NASDAQ. The stock is up 312% over the past year.
AnaptysBio, Inc. (ANAB) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ANAB earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Sep 2, 2026 | $-0.41 | $-0.31 | +25.0% | — | — |
| May 12, 2026 | $-0.32 | $-1.84 | -475.0% | $26M | +35.5% |
| Mar 3, 2026 | $0.89 | $1.58 | +77.5% | $108M | +24.3% |
| Nov 4, 2025 | $-1.06 | $0.52 | +149.1% | $76M | -12.4% |
| Feb 27, 2025 | $-1.61 | $-0.72 | +55.3% | $43M | +453.9% |
| May 9, 2024 | $-1.54 | $-1.64 | -6.5% | $7M | +80.8% |
| Mar 11, 2024 | $-1.74 | $-1.59 | +8.6% | $9M | +343.6% |
| Nov 2, 2023 | $-1.72 | $-1.41 | +18.0% | $3M | +44.3% |
| May 11, 2023 | $-1.04 | $-1.58 | -51.9% | $1M | -61.5% |
| Mar 1, 2023 | $-0.92 | $-0.93 | -1.1% | $7M | +17.7% |
| May 4, 2022 | $-0.87 | $-1.31 | -50.6% | $970000 | -80.8% |
| Mar 7, 2022 | $2.28 | $-1.13 | -149.6% | $1M | +3.6% |
ANAB insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Lizzul Paul F.officer: Chief Medical Officer | Grant | 16,667 | — |
| Aug 7, 2026 | Faga Danieldirector, officer: President, CEO | Grant | 53,334 | — |
| Jun 17, 2026 | Orwin John Adirector | Option | 6,030 | — |
| Jun 17, 2026 | RENTON HOLLINGSdirector | Option | 6,030 | — |
| Jun 17, 2026 | Schmid John P.director | Option | 6,030 | — |
| May 13, 2026 | Murphy Christopher M.officer: Chief Financial Officer | Grant | 25,765 | — |
| May 13, 2026 | Hughes Owendirector | Grant | 11,250 | — |
| Apr 29, 2026 | GRAY SUSANNAHdirector | Grant | 11,250 | — |
| Apr 22, 2026 | RENTON HOLLINGSdirector | Grant | 9,200 | $22.13 |
| Apr 22, 2026 | Schmid John P.director | Grant | 9,200 | $22.13 |
| Apr 22, 2026 | RENTON HOLLINGSdirector | Grant | 15,000 | $18.03 |
| Apr 22, 2026 | Faga Danieldirector, officer: President, CEO | Grant | 9,200 | $22.31 |
| Apr 22, 2026 | RENTON HOLLINGSdirector | Grant | 11,000 | $12.14 |
| Apr 22, 2026 | Orwin John Adirector | Grant | 10,600 | $14.29 |
| Apr 22, 2026 | RENTON HOLLINGSdirector | Grant | 6,000 | $76.79 |
Source: ANAB SEC Form 4 filings, latest Aug 7, 2026. For informational purposes only — not investment advice.
See the full ANAB insider & 13F page →AnaptysBio, Inc. company profile
Overview
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company founded in 2005 and based in San Diego, California. The company was originally incorporated as Anaptys Biosciences, Inc. before changing its name to AnaptysBio in July 2006. AnaptysBio went public in January 2017 and focuses on developing innovative therapeutic antibody candidates for treating inflammatory diseases and immuno-oncology conditions. The company leverages its proprietary antibody discovery platform to create targeted treatments that modulate immune system responses.
Business
AnaptysBio operates in the biotechnology sector, specifically focusing on developing monoclonal antibody therapeutics for inflammatory diseases and cancer immunotherapy. Monoclonal antibodies are laboratory-created proteins that can bind to specific targets in the body, either blocking harmful processes or enhancing beneficial immune responses. The company's pipeline centers around three main therapeutic candidates. Imsidolimab is an antibody that blocks the interleukin-36 receptor (IL-36R), a protein involved in inflammatory skin conditions. When IL-36R is overactive, it triggers excessive inflammation leading to diseases like hidradenitis suppurativa and palmoplantar pustulosis. By blocking this receptor, imsidolimab aims to reduce inflammation and improve symptoms. Rosnilimab represents a novel approach as an anti-PD-1 agonist antibody. Unlike typical cancer immunotherapies that block PD-1 to activate immune responses against tumors, rosnilimab actually enhances PD-1 signaling to suppress overactive T-cells that cause inflammatory diseases. This makes it potentially useful for autoimmune conditions where the immune system attacks healthy tissue. ANB032 is an anti-BTLA modulator antibody targeting B and T lymphocyte attenuator (BTLA), a protein that regulates immune cell activity. This candidate is designed to treat inflammatory diseases involving both lymphoid and myeloid immune cell dysfunction. The company also maintains various collaboration agreements with major pharmaceutical companies including GlaxoSmithKline and Bristol-Myers Squibb, which provide additional revenue streams and validation of their antibody discovery platform.
Revenue model
AnaptysBio generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners rather than product sales, as none of their therapeutic candidates have reached commercial approval yet. The company's 2024 revenue of $91.3 million came entirely from milestone payments, research funding, and licensing fees from partnerships with companies like GSK and Bristol-Myers Squibb. The business model relies on leveraging their proprietary antibody discovery platform to develop promising therapeutic candidates to a certain stage, then partnering with larger pharmaceutical companies that provide upfront payments, milestone payments as development progresses, and eventual royalties if products reach market. This approach allows AnaptysBio to reduce financial risk while maintaining upside potential. Key factors that could increase profitability include successful clinical trial results leading to larger milestone payments, additional partnership deals, and eventual royalty streams if any products reach commercialization. Conversely, clinical trial failures, competitive pressure from other immunology treatments, increased research and development costs, and the inherent high failure rate in drug development could negatively impact margins. The company faces the typical biotech challenge of high cash burn during the pre-revenue phase, with operating cash flow of negative $135.3 million in 2024. Success depends heavily on clinical trial outcomes and the ability to secure continued partnership funding or additional capital raises to sustain operations through the lengthy drug development process.
Competitive moat
AnaptysBio's competitive moat is relatively narrow but potentially significant in specific therapeutic areas. The company's primary advantage lies in its proprietary antibody discovery platform and its focus on novel mechanisms of action, particularly with rosnilimab's unique PD-1 agonist approach, which contrasts with the more common PD-1 antagonist therapies used in cancer treatment. The company's partnerships with major pharmaceutical companies like GSK and Bristol-Myers Squibb provide some validation of their technology platform and offer financial stability during development phases. However, these partnerships also limit AnaptysBio's control over key assets and future revenue potential. The biotech industry is highly competitive with low barriers to entry for well-funded competitors. Large pharmaceutical companies, other biotech firms, and academic institutions are all developing competing inflammatory disease treatments. The company's moat could strengthen significantly if their clinical trials demonstrate superior efficacy or safety profiles, particularly for imsidolimab in dermatological conditions where current treatment options are limited. The main threats to AnaptysBio's position include clinical trial failures, faster development of competing therapies, patent expirations, and the possibility that larger companies could develop similar antibody discovery capabilities in-house. The company's survival and success depend heavily on achieving positive clinical outcomes and maintaining strategic partnerships.
Risks & safety
AnaptysBio presents moderate financial risk typical of clinical-stage biotechnology companies, with adequate short-term liquidity but ongoing cash burn concerns. • **Cash Position**: $123.1 million in cash and short-term investments as of Q4 2024, providing approximately 1-2 years of runway based on current burn rates • **Cash Burn**: Negative operating cash flow of $135.3 million in 2024, with quarterly burn rates fluctuating between $10-67 million • **Debt Level**: Relatively low debt-to-equity ratio of 0.23, indicating conservative capital structure • **Liquidity**: Strong current ratio of 9.5x and quick ratio of 9.5x, showing excellent short-term liquidity • **Valuation**: Trading at 2.6x price-to-book ratio, which appears reasonable for a clinical-stage biotech • **Solvency Risk**: Moderate risk requiring either successful clinical milestones, partnership payments, or additional capital raises within 12-24 months The company's financial position is strengthened by partnership revenues and milestone payments, but the unpredictable nature of clinical development creates inherent uncertainty about future cash needs and timeline to profitability.
Recent development
Based on the financial data patterns, AnaptysBio has been advancing its clinical pipeline with several key developments over recent years. The company has maintained steady partnership revenue streams, with 2024 showing significantly higher revenue of $91.3 million compared to $17.2 million in 2023, suggesting major milestone achievements or new partnership agreements. The fluctuating quarterly revenues indicate milestone-based income from clinical trial progress, particularly strong performance in Q4 2024 with $43.1 million in revenue. The company appears to have strengthened its cash position through partnership deals, with cash levels recovering from a low of $36 million in 2023 to $123 million by end of 2024. Research and development expenses have remained consistently high, reflecting continued investment in advancing their three main therapeutic candidates through clinical trials. The company has maintained its focus on inflammatory diseases and immuno-oncology, with particular emphasis on advancing imsidolimab for dermatological conditions and developing the novel rosnilimab PD-1 agonist approach. Strategic partnerships continue to play a crucial role in the company's development strategy, providing both financial support and validation of their antibody discovery platform. The revenue increases suggest successful achievement of clinical milestones that triggered partnership payments, indicating progress in their development programs.
ANAB company profile · for informational purposes only — not investment advice.
Track ANAB with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free